Tryp Therapeutics Inc.
TRYPF · OTC
2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $1 | $1 | $0 |
| SG&A Expenses | $0 | $1 | $1 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $1 | $1 | $1 |
| Operating Income | -$0 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | -$0 | -$1 | -$0 |
| Pre-Tax Income | -$0 | -$1 | -$2 | -$1 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$0 | -$1 | -$2 | -$1 |
| % Margin | – | – | – | – |
| EPS | -0 | -0.012 | -0.018 | -0.007 |
| % Growth | 99.7% | 31.4% | -157.4% | – |
| EPS Diluted | -0 | -0.012 | -0.018 | -0.007 |
| Weighted Avg Shares Out | 96 | 96 | 96 | 96 |
| Weighted Avg Shares Out Dil | 96 | 96 | 96 | 96 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | -$0 | $0 |
| EBITDA | -$0 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |